The U.S. Supreme Court decision that Myriad Genetics cannot patent two genes linked to ovarian and breast cancer came as welcome relief to researchers working on BRCA1 and BRCA2 genes.    

Title: Ovarian Cancer : 4 Early SymptomsCategory: Health NewsCreated: 6/14/2007 12:00:00 AMLast Editorial Review: 6/14/2007 12:00:00 AM

On Thursday, the Supreme Court ruled that companies cannot patent isolated human genes that are naturally occurring. The decision defeats the Salt Lake City company, Myriad Genetics Inc. who had previously been granted patents on the BRCA1 and BRCA2 genes that put women at a greater risk for breast and ovarian cancer—a topic that gained more attention when actress Angelina Jolie revealed ...

The Supreme Court has finally done what should have been done years ago -- declared that genes which naturally exist in all of us cannot be patented.  For years Myriad Genetics, the company that sells the genetic tests used by Angelina Jolie and thousands of other women to assess their risk of breast cancer and ovarian cancer, has held back ...

(MedPage Today) -- Median progression-free survival in patients with recurrent ovarian cancer was boosted by 1.8 months with a novel targeted therapy in a phase III trial, its sponsor said.